BioNote, Inc. (KRX:377740)
South Korea · Delayed Price · Currency is KRW 4,760.00
-5.00 (-0.10%)
At close: Sep 11, 2026
BioNote Revenue
BioNote had revenue of 36.37B KRW in the quarter ending June 30, 2026, with 12.23% growth. This brings the company's revenue in the last twelve months to 126.41B, up 12.82% year-over-year. In the year 2025, BioNote had annual revenue of 118.32B with 15.12% growth.
Revenue (ttm)
126.41B
Revenue Growth
+12.82%
P/S Ratio
3.80
Revenue / Employee
422.76M
Employees
298
Market Cap
480.35B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 118.32B | 15.54B | 15.12% |
| Dec 31, 2024 | 102.78B | 12.70B | 14.10% |
| Dec 31, 2023 | 90.08B | -389.58B | -81.22% |
| Dec 31, 2022 | 479.66B | -142.70B | -22.93% |
| Dec 31, 2021 | 622.36B | -9.15B | -1.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| SD Biosensor | 738.76B |
| Value Added Technology | 441.04B |
| i-SENS | 326.19B |
| InBody Co.,Ltd | 263.89B |
| T&L Co., Ltd. | 175.16B |
| WON TECH | 167.35B |
| DRTECH | 126.23B |
| SEERS | 97.05B |